1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Locus Cell Co., Ltd.

Locus Cell Co., Ltd.

TTPEX:6891
40.65
TWD
-1.35
(-3.21%)
-0.55EPS
6.42BMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
0.06
0.01
Basic EPS, GAAP
- -
-0.27
-0.27
-0.48
-0.57
-0.91
-0.55
Free Cash Flow per Basic Share
- -
-0.24
-0.31
-0.81
-2.76
-3
-2.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
9.83
9.57
9.13
8.61
7.75
8.89
Tangible Book Value per Share
- -
9.83
9.57
9.11
8.58
7.72
8.88
Basic Weighted Avg Shares
200
127
200
200
200
200
199
Sales/Revenue/Turnover
- -
- -
1
- -
2
13
1
Operating Margin (%)
- -
- -
-15,357.17
-34,588.18
-6,721.77
-1,370.51
-14,941.73
Depreciation Expense
- -
4
11
17
25
32
21
Net Income, GAAP
- -
-35
-53
-97
-113
-182
-109
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-8,913
-23,865.52
-4,796.99
-1,425.2
-10,512.4
Working Capital
1
1,957
1,873
1,699
1,149
774
1,366
LT Debt
- -
63
68
63
58
284
59
Total Equity
1
1,965
1,914
1,826
1,723
1,551
1,779
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-3.51
-2.76
-5.18
-6.37
-11.09
-5.98

Capital Structure

TWD

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
14
13
12
LT Borrowings
- -
- -
- -
LT Finance Leases
63
60
59
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
200
200
200
Market Capitalization
6,300
4,990
6,420

Working Capital

TWD

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
1,725
1,620
1,454
Cash, Cash Equivalents & STI
1,713
1,600
1,424
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
27
31
88
Payables & Accruals
- -
- -
- -
ST Debt
14
13
12
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41,926.74%
-9.97%
Free Cash Flow
- -
- -
8.84%
Net Income, GAAP
- -
10,980.77%
60.63%
Sales/Revenue/Turnover
- -
- -
440.66%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2
2025
- -
- -
13
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.57
2025
- -
- -
-0.91
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yu Hsiang Chang
Full Time Employees
51
Sector
Health technology
Industry
Biotechnology
Address
No.97, Xintai 5th Road New Taipei Taiwan 22175
IPO Date
Apr 28, 2022
Website
locus-cell.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Locus Cell Co., Ltd. (6891.TWO) is a Taiwan-based contract development and manufacturing organization (CDMO) specializing in regenerative medicine and cell and gene therapy products. The company provides comprehensive cell therapy CDMO services, including process development and scale-up, analytical method development and validation, clinical GMP manufacturing for trials, and stability testing, utilizing a PIC/S GMP-compliant facility in Hsinchu Biomedical Science Park; its offerings encompass tissue engineering products, CAR-T therapies, iPSCs, MSCs, and other cell therapy applications such as adipose-derived stem cells, nerve cells, chondrocytes, fibroblasts, and epithelial cells. Founded in 2020 and headquartered at 19/F-12, No. 97, Section 1, Xintai 5th Road, New Taipei City, Taiwan, Locus Cell operates primarily in Taiwan with a focus on global pharmaceutical clients and maintains partnerships with Hitachi Group and industry experts from Minaris. In September 2025, the company signed its first international Phase III CDMO memorandum of understanding with Australia-based Cambium Bio to handle contract development and manufacturing of Elate Ocular, a dry eye disease therapy in Phase III trials, covering all international clinical and commercial production outside the Middle East and Europe.